Revvity (NYSE:RVTY) Updates FY 2025 Earnings Guidance

Revvity (NYSE:RVTY) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 5.000- for the period, compared to the consensus estimate of 4.910. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion. Revvity also updated its Q4 2025 guidance to EPS.

Revvity Stock Up 5.9%

RVTY stock opened at $110.01 on Wednesday. The company’s 50 day moving average is $98.67 and its two-hundred day moving average is $94.17. Revvity has a twelve month low of $81.36 and a twelve month high of $128.29. The company has a current ratio of 1.75, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The stock has a market cap of $12.47 billion, a P/E ratio of 55.28, a PEG ratio of 3.18 and a beta of 1.05.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, October 27th. The company reported $1.18 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.04. Revvity had a net margin of 8.44% and a return on equity of 7.52%. The firm had revenue of $698.95 million for the quarter, compared to the consensus estimate of $699.75 million. During the same period last year, the firm posted $1.28 EPS. The company’s revenue was up 2.2% on a year-over-year basis. Revvity has set its FY 2025 guidance at 4.900-5.000 EPS. Research analysts expect that Revvity will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 6th. Stockholders of record on Friday, January 16th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, January 16th. Revvity’s payout ratio is presently 14.07%.

Revvity announced that its board has authorized a stock buyback plan on Monday, October 27th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to repurchase up to 8.7% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on RVTY shares. Bank of America cut Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price objective for the company. in a research note on Monday, December 15th. Wells Fargo & Company upped their price target on shares of Revvity from $102.00 to $107.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Guggenheim began coverage on shares of Revvity in a research report on Wednesday, October 15th. They set a “neutral” rating on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Revvity in a report on Monday, December 29th. Finally, Evercore ISI reiterated an “outperform” rating on shares of Revvity in a research note on Monday, January 5th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $113.91.

Trending Headlines about Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Updated guidance — Revvity raised Q4 2025 revenue guidance to roughly $772 million and set FY‑2025 EPS around the top of its prior range (targeting ~5.00 EPS) and FY revenue roughly $2.9 billion, both above consensus estimates; this is the primary driver of the rally.
• Positive Sentiment: Company statement: management said Revvity expects to exceed its previously announced 2025 adjusted profit per share range, citing renewed demand for contract research and diagnostics services, which supports margin and earnings upside. Revvity says it will exceed 2025 profit forecast range
• Positive Sentiment: Market reaction coverage — media and research outlets highlighted that Revvity’s Q4 revenue outlook topped expectations, driving premarket interest and buy‑side momentum. Why Is RVTY Stock Surging in Premarket? Q4 Revenue Outlook Tops Expectations
• Positive Sentiment: Earnings/guidance coverage — reporters noted Revvity’s guidance was above consensus, which analysts interpret as validation of demand trends in its contract research and diagnostics end markets. Revvity trades higher on earnings guidance above consensus
• Positive Sentiment: Strategic partnership — Revvity and Eli Lilly are partnering to expand access to AI drug‑discovery models via Revvity’s Signals Xynthetica platform, which could broaden product/service stickiness and open new revenue streams over time. RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models
• Neutral Sentiment: Investor presentation — Revvity presented at the J.P. Morgan Healthcare Conference (management remarks and strategy transcript available); this provided execution detail but no major surprises. Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Upcoming earnings call — Revvity will report Q4/FY2025 results and host a Feb. 2 earnings call; this is the next event to watch for whether management’s guidance is confirmed and for detailed segment metrics. Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

Hedge Funds Weigh In On Revvity

Large investors have recently made changes to their positions in the stock. CYBER HORNET ETFs LLC purchased a new stake in Revvity during the 2nd quarter worth about $32,000. MUFG Securities EMEA plc purchased a new stake in shares of Revvity during the second quarter worth about $34,000. Headlands Technologies LLC purchased a new stake in shares of Revvity during the second quarter worth about $49,000. EverSource Wealth Advisors LLC raised its position in shares of Revvity by 25.9% in the second quarter. EverSource Wealth Advisors LLC now owns 900 shares of the company’s stock valued at $87,000 after buying an additional 185 shares during the last quarter. Finally, Nomura Holdings Inc. purchased a new stake in Revvity in the 3rd quarter worth approximately $270,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.